Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021
Essink, Sharon C. M., Zomerdijk, Inge M., Straus, Sabine M. J. M., Gardarsdottir, Helga, De Bruin, Marie L.
Published in Drug safety (01.10.2023)
Published in Drug safety (01.10.2023)
Get full text
Journal Article
Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe
Francisca, Reynold D. C., Baba, Emna, Hoeve, Christina E., Zomerdijk, Inge M., Sturkenboom, Miriam C. J. M., Straus, Sabine M. J. M.
Published in Drug safety (01.01.2021)
Published in Drug safety (01.01.2021)
Get full text
Journal Article
Risk Minimization Activities of Centrally Authorized Products in the EU: A Descriptive Study
Zomerdijk, Inge M., Sayed-Tabatabaei, Fakhredin A., Trifirò, Gianluca, Blackburn, Stella C. F., Sturkenboom, Miriam C. J. M., Straus, Sabine M. J. M.
Published in Drug safety (01.04.2012)
Published in Drug safety (01.04.2012)
Get full text
Journal Article
Additional risk minimisation measures in the EU- are they eligible for assessment?
Zomerdijk, Inge M., Trifirò, Gianluca, Sayed-Tabatabaei, Fakhredin A., Sturkenboom, Miriam C. J. M., Straus, Sabine M. J. M.
Published in Pharmacoepidemiology and drug safety (01.10.2013)
Published in Pharmacoepidemiology and drug safety (01.10.2013)
Get full text
Journal Article